Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
Tue, 28.07.2026       HELIOS SOLAR AG

HELIOS SOLAR AG (“HELIOS” or the “Company”; ISIN: DE000A42D2N5, WKN: A42D2N, stock exchange symbol: HE8) announces that the Company has successfully completed a further private placement. Four million shares were privately placed with an institutional investor in Asia at a price of four euros per share. The privately placed shares are unsubscribed [ … ]
Tue, 28.07.2026       Reinet Investments SCA

Reinet Investments S.C.A. has repurchased 634 767 ordinary shares in the period 20 July 2026 to 24 July 2026. The shares were repurchased on the Johannesburg Stock Exchange at an average price of ZAR 441.28 per share (highest price: ZAR 456.46; lowest price: ZAR 430.85) for a total consideration of some ZAR 280.1 million (€ 14.8 million), plus tran [ … ]
Tue, 28.07.2026       Schlatter Industries AG

SCHLATTER INDUSTRIES AG - SIX SWISS EXCHANGE: STRN - ISIN: CH0002277314Ad hoc announcement pursuant to article 53 LR    Schlieren, 28 July 2026. The Board of Directors of Schlatter Industries AG has approved changes to the Executive Board, thereby implementing the long-term succession plan for the company’s operational management. Mr Werner Schmid [ … ]
Mon, 27.07.2026       Hypoport SE

Inside information pursuant to article 17 of the Market Abuse Regulation (MAR)   Hypoport SE: Gross profit growth and significant increase in EBIT in H1/26   Berlin, 27 July 2026: In today's board meeting, the preliminary business figures of the Hypoport Group for the first quarter of 2026 and the first half of 2026 were evaluated.   On this  [ … ]
Mon, 27.07.2026       Pentixapharm Holding AG

Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today   Pentixapharm Holding AG has successfully completed the capital increase announced on 1 July 2026. The private placement which was conducted subsequent to the rights offerin [ … ]
Mon, 27.07.2026       Lenzing AG

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THIS COMMUNICATION. Lenzing AG advances strategic transformation with focus on nonwoven applications  [ … ]
Mon, 27.07.2026       Sirma Group JSC

Reporting of transactions pursuant to Article 5 (1) (b) of Regulation (EU) No 596/2014 (Market Abuse Regulation – “MAR”) in conjunction with Article 2 (2) and (3) of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (Share Buyback Regulation – “SBR”). Transactions in own shares Further to the announcement of 17 June 2026 regarding th [ … ]
Mon, 27.07.2026       HOCHTIEF Aktiengesellschaft

The Executive Board of HOCHTIEF has today decided to raise its operational net profit guidance for the 2026 financial year to between EUR 1,025 million and EUR 1,100 million. This represents an increase of approximately 30% to 40% year on year. Previously, HOCHTIEF had guided for operational net profit of between EUR 950 million and EUR 1,025 milli [ … ]
Sun, 26.07.2026       Kapsch TrafficCom AG

Kapsch TrafficCom reaches agreement with its major financial creditors on key terms of a restructuring.Vienna, July 24, 2026 – Kapsch TrafficCom AG (ISIN: AT000KAPSCH9; the “Company”) has concluded a standstill agreement and a binding term sheet with its major financial creditors (lenders and promissory note creditors) as the basis for a comprehens [ … ]
Fri, 24.07.2026       BB BIOTECH AG

Ad hoc announcement pursuant to Art. 53 LR July 24, 2026 BB Biotech AG publishes its interim report and revises its dividend policy BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2026, which covers the results of its business activities for the first six months of 2026. Based on the consolidated accounts of  [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

© 2026 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2026 WEBs Investments ETFs
Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 12.10.2026, Calendar Week 42, 285th day of the year, 80 days remaining until EoY.